Quantifying Bevacizumab Efficacy in Recurrent Respiratory Papillomatosis

Area of Science:

• Otolaryngology
• Medical Imaging
• Pharmacology

Background:

• Recurrent Respiratory Papillomatosis (RRP) poses significant treatment challenges.
• Bevacizumab (Bev) is an emerging therapeutic option for RRP.
• Standardized efficacy assessment for RRP treatments is needed.

Purpose of the Study:

• To develop and validate a novel ImageJ-based method for quantifying Bevacizumab (Bev) efficacy in Recurrent Respiratory Papillomatosis (RRP).
• To evaluate clinical outcomes of a three-dose Bev induction therapy followed by surgery in RRP patients.

Main Methods:

• Twenty-one RRP patients received a three-dose Bev regimen.
• A novel ImageJ software method was developed to calculate standardized lesion volume from laryngoscopic images.
• The novel method was compared with the Derkay score; clinical outcomes were analyzed.

Main Results:

• The novel efficacy evaluation method showed significant positive correlation with the Derkay score.
• Bev treatment demonstrated a high overall response rate, increasing from 75% to 100% after three doses.
• While 76% of surgically treated patients experienced recurrence, lesions were generally smaller post-treatment; hypertension was the main adverse event.

Conclusions:

• Systemic Bevacizumab (Bev) is a safe and effective treatment for Recurrent Respiratory Papillomatosis (RRP).
• The developed ImageJ-based efficacy evaluation method aids in studying Bev treatment effectiveness for RRP.
• Further research is warranted to fully elucidate the long-term impact of Bev therapy in RRP management.